Drug Profile
P 081
Alternative Names: RimostilLatest Information Update: 12 Dec 2017
Price :
$50
*
At a glance
- Originator Novogen
- Class Isoflavones
- Mechanism of Action Estrogen receptor agonists; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cardiovascular disorders; Hyperlipidaemia; Postmenopausal osteoporosis
Most Recent Events
- 24 Apr 2007 Discontinued - Phase-II for Cardiovascular disorders in Australia (unspecified route)
- 24 Apr 2007 Discontinued - Phase-II for Hyperlipidaemia in Australia (unspecified route)
- 24 Apr 2007 Discontinued - Phase-II for Postmenopausal osteoporosis in Australia (unspecified route)